Back to News
Market Impact: 0.35
HeartSciences Wins FDA Clearance For MyoVista WavECG; Fortitude Lines Up $100 Mln Miner Deal
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct LaunchesTechnology & Innovation
The FDA granted 510(k) clearance for HeartSciences' MyoVista wavECG device. HeartSciences submitted the device for review in December 2025; the article provides no additional commercial, financial, or market-reaction details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
HSCS0.75
More News
- Singapore's Temasek warns of the ‘biggest risk’ facing markets right now
- Australia top court rules against coal mine expansion, citing climate harm
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- What Marvell's rosy long-term guidance means for our AI chip stocks
- Paramount and Warner Bros. Discovery complete $110 billion media megamerger